A cetaminophen is widely used as a pediatric analgesic and antipyretic. Although safe and effective when used as directed, acetaminophen is also associated with a large number of unintentional overdoses. Acetaminophen overdoses can result in acute liver failure and were responsible for 14% of all cases of pediatric acute liver failure in 1 large cohort, 1 and 19% of pediatric liver transplant cases in another series. 2 These overdoses may result from unintentional medication errors or from accidental unsupervised ingestions (AUI) by children. Emergency department visits for unintentional acetaminophen overdoses in children under the age of 6 years are 10-fold more likely to be due to AUIs than medication errors, with visit rates for AUIs of acetaminophen estimated at 42.5 visits per 100 000 population per year. 3 In the US from 2010 to 2013, AUIs in children less than 6 years old of liquid acetaminophen products led to an estimated 2607 emergency visits per year. 4 Thus, pediatric AUIs of acetaminophen continue to represent personal and public health burdens.
Initiatives have been launched to decrease the number of pediatric acetaminophen overdoses and their severity, including safety awareness campaigns and packaging innovations. [5] [6] [7] [8] [9] In 2011, nonprescription acetaminophen manufacturers voluntarily introduced flow restrictors into pediatric liquid acetaminophen products. 10 Flow restrictors have been shown to be effective in reducing liquid medication access in the research setting. 9 The introduction of flow restrictors was coupled with the standardization of pediatric liquid acetaminophen concentrations at 160 mg per 5 mL and the inclusion of an in-package dosing device to decrease medication dosing errors.
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The current study assessed the temporal relationship between introduction of flow restrictors and pediatric AUIs of single ingredient acetaminophen products from 2007 to 2015 using National Poison Data System (NPDS) data. 
Methods
This was a study of exposures reported to the NPDS, a repository for all exposures received by regional poison centers (RPCs) throughout the US and maintained by the American Association of Poison Control Centers. RPC staff collect information using standardized data systems designed to obtain key information, including patient's age, products involved, circumstances of the exposure, and estimated amount ingested. Exposures are followed until no further follow-up or recommendations are required or no further information is available.
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All exposures are assigned a "reasons" code based on the history provided (eg, medication error, AUI). Case follow-up is done to obtain the medical outcome and is completed in an average of 46.8% of exposures reported to the NPDS. 12 Details on NPDS methodologies can be found in their annual report. 12 NPDS exposures included in the current analysis involved ≥1 single ingredient acetaminophen product, with or without other substances, categorized as an AUI, and occurring in a child <12 years of age (or an estimated age of ≤5 years if the exact age could not be determined). In addition, all NPDS pharmaceutical exposures were extracted from the 2007-2015 NPDS annual reports to provide context for trends in reported exposures. [12] [13] [14] [15] [16] [17] [18] [19] [20] Six RPCs collected follow-up information on exposures involving single ingredient acetaminophen products between August 2013 and January 2016. Information on the specific product(s) involved, awareness of medication safety, and possible contributing factors were obtained using a custom designed survey tool. Information was obtained only if the individual making the original call to the RPC was the child's caregiver (eg, not a healthcare provider), and was available and agreed to participate.
Survey personnel were trained to assess the presence or absence of new packaging features using questions such as, "When you look at the bottle, is there a restricted or smaller opening which you have to use a syringe to get the medication out?", "Do you have to squeeze the bottle to get any medicine out?", "Does the top of the bottle have an opening that allows the medication to flow out freely without squeezing?", and "Did the medication come with a syringe?".
RPCs received ethics approval by their local institutional review board to conduct the surveys and submit deidentified case narratives. Survey participants provided verbal consent.
Unit sales (ie, bottles or blister packs) from food, drug, and other major retailers were obtained from Information Resources, Inc (Chicago, Illinois) from 2010 to 2015. These data were used to generate annual rates of exposure per million units sold.
Statistical Analyses
The data presented are descriptive; no prospective inferential hypothesis testing was defined. Therefore, no P values were calculated and data are presented as observed absolute values, means with SDs, or medians with IQR. Time trends were estimated using linear regression. Although changes in acetaminophen packaging was introduced in 2011, 2012 was used as the transition year for assessments owing to the time required to introduce manufacturing changes, turnover of store shelf product, and turnover of home product stocks. An iterative fitting technique of single breakpoint piecewise linear regression models was used post hoc to analyze the best fit of a transition year by comparing mean squared error values. Analyses were completed in 2017 and were conducted using SAS (version 9.4; SAS Institute, Cary, North Carolina). A breakpoint analysis confirmed that 2012 was the optimal transition year in the time series. In contrast, total AUIs including all substances decreased at a slow, relatively consistent rate for the period 2007-2015 without evidence of a change in rate after 2011 ( Table I) .
Results

From
The age distribution of patients exposed via AUI of single ingredient acetaminophen products was stable over the 9 years of observation ( Table II) . The median age was 2 years and 96.3% of exposures involved children <6 years of age. Approximately 52.0% of the patients were male and 96.9% of exposures occurred in the child's own residence. The vast majority (93.4%) of the exposures involved only a single product.
Exposures involved ingestion of liquid or solid single ingredient acetaminophen formulations, and rarely (0.1% of all exposures) both. Annual exposure counts decreased over the Annual numbers of AUIs involving any substance in children ≤5 years of age were tabulated and the percent change from the previous year calculated.
Volume 198 • July 2018 9-year observation period for each formulation type (Table III) (Table III ). In contrast, sales of solid formulations decreased from 92.2 million units in 2010 to 68.4 million units in 2012 followed by a recovery to 74.6 million units in 2015 (Table III) . This time course of liquid and solid products reflects manufacturing problems and product recalls by a major manufacturer of acetaminophen products. 21 These sales data were used to normalize the observed rate of NPDS exposures for single ingredient acetaminophen exposures. Exposures associated with liquid products were more common than those with solid formulations when normalized to sales (Figure, B) . Notably, NPDS exposures involving liquid single ingredient acetaminophen products per million units sold decreased by almost 40.0% from 2010 to 2015, while exposures involving solid formulations showed no clear pattern over the same period (Figure, B) .
The majority (79.9%) of the NPDS exposures for AUIs of single ingredient liquid acetaminophen products did not result in a referral to a health care facility, and 82.6% of those exposures referred to a facility were released without admission. The numbers of exposures admitted to noncritical care or critical care units were small (approximately 70-90 and 25-60 per year, respectively) without clear temporal trends over the observation period (data not shown). Over the 9 years 
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From 2007 to 2015, old single ingredient acetaminophen pediatric liquid formulations and packaging types were identified in 20 920 exposures, of which 2.4% were admitted to noncritical care units and 1.5% to critical care units. In contrast, 3210 of the exposures involved single ingredient acetaminophen pediatric liquid products using the new formulation and packaging, of which 1.2% were admitted to noncritical care units and 0.8% to critical care units.
RPC Supplemental Survey
and weight information from which a mg/kg amount ingested could be calculated. One hundred forty of these involved a pediatric liquid with old formulation and packaging, 562 had new formulation and packaging incorporating flow restrictors, and in 27 exposures the packaging could not be identified. Ingestions involving old packaging had a greater average estimated ingested dose as compared with those involving new packaging (Table IV; available at www.jpeds.com). Importantly, estimated ingestions with old formulations were almost twice as likely to exceed a threshold of 150 mg/kg, a dose suggested to be associated with increased risk of liver toxicity 22 (Table IV) . Commonly mentioned contributing factors to the child's ingestions included improper storage, often associated with recent use, and confusion of the drug by the child with candy or treat (Table V; available at www.jpeds.com). Many of the respondents (70.8%) suggested the medication was outside the normal storage area when accessed by the child. Failure to secure the child-resistant closure was cited in 47.6% of the responses.
Discussion
In 2011, flow restrictors were introduced for liquid acetaminophen products in an effort to decrease both the frequency and clinical sequalae of accidental ingestions. The current analysis of NPDS data demonstrates that the introduction of flow restrictors was associated with a decrease in the number of accidental pediatric exposures involving liquid acetaminophen products. The steady decrease in exposures after 2011 may reflect the slow replacement of old acetaminophen products with flow-restrictor equipped products, first on store shelves and then in consumers' homes.
NPDS received >20 000 exposures per year for accidental acetaminophen ingestions between 2007 and 2015. Approximately 80% of these exposures resulted in a recommendation that no health care provider follow-up was required, and only approximately 100 exposures per year resulted in hospitalization. Packaging of pediatric liquid acetaminophen with Table II a flow restrictor was associated with lower estimates of drug ingestion per exposure and a lower rate of exposures that exceeded thresholds potentially associated with hepatic injury. Further, exposures involving flow restrictor equipped products were associated with admission to critical and noncritical care units at about one-half the rate observed with exposures involving old packaging. Nonetheless, some estimated ingested doses involving flow restrictor products were >150 mg/ kg, further emphasizing the need for safe medication storage and continued improvement in flow restrictor technology (factors such as orifice size and valve design).
Household availability of acetaminophen products may be a factor in the determining rates of pediatric accidental ingestions. Most of the analyzed NPDS exposures occurred in the child's own residence. Improper storage is an important contributing factor to AUIs involving acetaminophen. Consistent with a previous study, 23 recent use of the ingested product was identified as a risk factor. During each of the years examined, exposures peaked in the winter months (cold/flu season) when increases in acetaminophen use are expected, with the winter peak month exposures rate approximately 1.3 times the summer month nadir (data not shown).
Several other initiatives may have also impacted the rate of acetaminophen AUIs. In 2009, the US Food and Drug Administration strengthened the labeled liver warning on nonprescription products containing acetaminophen 24 and research demonstrates that the revised labeling better communicates this risk to consumers, 25 potentially leading to safer medication storage behaviors. Safe Kids Worldwide has worked to call attention to childhood poisoning and promoted preventive behaviors. 5 In 2008, the Centers for Disease Control and Prevention and its partners launched the PROTECT initiative to decrease pediatric drug poisonings. 6 The PROTECT initiative launched the "Up and Away and Out of Sight" campaign in collaboration with the Consumer Healthcare Products Association and other PROTECT partner organizations to educate parents and caregivers on proper medication storage to prevent AUIs. 7 The concentration of acetaminophen in liquid pediatric products was standardized at 160 mg per 5 mL, removing the more concentrated 80 mg per 0.8 mL formulations from the market.
11, 21, 26 The reporting of contributing factors supports a multifactorial etiology for the public health burden of accidental acetaminophen ingestions, and thus a multifactorial approach to interventions should also be encouraged. The non-acetaminophen-specific initiatives may have contributed to the observed decrease in all AUIs in children <6 years of age.
Limitations to the current study include those inherent to the NPDS and RPC survey methodologies. Not all ingestions may lead to a call to an RPC. For example, the child may be taken directly to an emergency department without any RPC contact by the child's caregiver or the medical staff. Further, the data collected by the RPC may be incomplete or inaccurate because they are based solely on caller reporting, and clinical follow-up was available for only 46.8% of exposures. Estimates of the amount of drug ingested are crude, and should not be viewed as truly quantitative. In many exposures, even after follow-up calls in the RPC cohort, either the estimated ingested dose and/or the type of packaging could not be determined, potentially biasing the conclusions. Nonetheless, because NPDS methodologies have been consistent over time, trends over time are still likely to be informative. Although flow restrictors were universally introduced, there is no standardization of flow restrictor performance, and the specific flow restrictor type associated with each exposure was not identified. Thus, residual heterogeneity among packaging characterized as "new" is likely. Finally, temporal trends can only identify associations and not casualty. Other potentially relevant changes, as detailed, occurred at approximately the same time as flow restrictor introduction and may have contributed to the changes observed as evidence by the decrease in total AUIs in children <6 years of age. The standardization of pediatric liquid products at 160 mg per 5 mL may be particularly relevant, because any volume of exposure would result in a lower acetaminophen dose to the child. Nonetheless, the totality of the evidence supports a key role for flow restrictors. First, overall NPDS exposures remained relatively constant, as did solid acetaminophen formulation exposures when corrected for sales. Although total AUIs in children <6 years of age decreased, there was no evidence of a breakpoint in the time trend nor of an acceleration after 2011. Second, estimates of the amount ingested by the child were lower with flow restrictor packaging as compared with older packaging. This finding suggests that many exposures were avoided or were of small quantities and, thus, did not result in calls. Third, laboratory testing of flow restrictors provides plausibility for the observed association. The current observations are consistent with the use of flow restrictors decreasing the frequency and severity of pediatric AUIs of acetaminophen. Efforts to expand the use of flow restrictors and to optimize their performance should be encouraged. Such innovative strategies for controlling the delivery of liquid medications may be relevant to other products at risk for accidental ingestion by children. 
